Mereo Biopharma Group Plc ADR [MREO] stock is trading at $4.33, up 6.13%. An important factor to consider is whether the stock is rising or falling in short-term value. The MREO shares have gain 14.55% over the last week, with a monthly amount glided 11.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mereo Biopharma Group Plc ADR [NASDAQ: MREO] stock has seen the most recent analyst activity on June 13, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $8. On August 12, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $4 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $10 on May 05, 2021. Needham initiated its recommendation with a Buy and recommended $10 as its price target on April 05, 2021.
Mereo Biopharma Group Plc ADR [MREO] stock has fluctuated between $1.07 and $4.50 over the past year. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. Mereo Biopharma Group Plc ADR [NASDAQ: MREO] shares were valued at $4.33 at the most recent close of the market. An investor can expect a potential return of 55.89% based on the average MREO price forecast.
Analyzing the MREO fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -38.66%, Pretax Profit Margin comes in at -37.69%, and Net Profit Margin reading is -37.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.63 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.15 points at the first support level, and at 3.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.43, and for the 2nd resistance point, it is at 4.52.
Ratios To Look Out For
For context, Mereo Biopharma Group Plc ADR’s Current Ratio is 6.07. On the other hand, the Quick Ratio is 6.07, and the Cash Ratio is 5.65. Considering the valuation of this stock, the price to sales ratio is 75.74, the price to book ratio is 8.47.
Transactions by insiders
Recent insider trading involved Sermon Charles, General Counsel, that happened on Jun 26 ’24 when 32187.0 shares were sold. General Counsel, Sermon Charles completed a deal on Jun 25 ’24 to sell 14202.0 shares. Meanwhile, Chief Scientific Officer Lewicki John A. sold 16808.0 shares on Jun 26 ’24.
